Observation on the curative effect of lamivudine in the treatment of chronic hepatitis b

Abstract

Objective To observe the curative effect and harmful reactions of lamivudine in the treatment of chronic hepatitis B. Methods A total of 121 cases patients with hepatitis B were at random divided into observation group of 69 cases and control group of 52 cases. The patients in the observation group oralIy took the laminvudine of 100 mg, one time a day. The patients in the control group were carried out the muscle injection of recombinant human interferon a-2b of 3,000,000 IU, one time a day. 2 weeks later,it was one time every other day. The vitamins and general hepatoprotectants were all additionally used in the observation group and control group and without the other anti-virus drugs added. After one-year's treatment,the curative effects ( serum ALT recovery rate, HBeAg negative conversion rate and serum HBV DNA negative conversion rate ) and harmful reactions in two groups were observed. The χ2 test for recovery rates and negative conversion rates in the control group and treatment group had been carried out. Results After one-year's treatment, the serum ALT recovery rate was 91.30% ( 63/69 ), HBeAg negative conversion rate was 52.17% ( 36/69 ) and serum HBV DNA negative conversion rate was 86.96% ( 60/69 ) in the observation group. In the control group, the serum ALT recovery rate was 42.31% ( 22/52 ), HBeAg negative conversion rate was 30.77% ( 16/52 ) and serum HBV DNA negative conversion rate was 48.08% ( 25/52 ). The differences had statistical significance (P＜0.05). The by-effect of lamivudine was lower than that of recombinant human interferon a-2b. Conclusions The lamivudine is an effective drug in the treatment of chronic hepatitis B. After one-year's successive treatment, the liver function becomes normal, viruses become negative and the sero-conversion is obvious. All of these are better than interferon. Therefore, it is valuable for clinical popularization. Key words: Laminvudine; Interferon; Chronic hepatitis B